Yes, but the statin dose may need to be reduced to avoid increased exposure. Your clinician will assess the appropriate statin dose when adding bempedoic acid.
Clinical studies have not shown a clinically significant impact on glucose metabolism, but routine monitoring is advisable for patients with diabetes.
Because bempedoic acid is activated primarily in the liver and not in skeletal muscle, it has a lower risk of muscle-related side effects. However, rare myalgias have been reported.
Both contain the same active ingredient at 180 mg. The differences lie only in excipients and packaging; therapeutic effect is equivalent.
No direct pharmacokinetic interaction has been identified, but routine INR monitoring is recommended when any new medication is added.
Contact your healthcare provider promptly. They may adjust the dose, add urate-lowering therapy, or switch to an alternative lipid-lowering agent.
Carry a copy of your prescription and a medication list in case you need pharmacy services abroad. Bempedoic acid does not require refrigeration, making it travel-friendly.
Noticeable reductions are often observed within two weeks, with the full effect reaching a plateau around three months of continuous use.
Eligibility for NHS prescription depends on meeting clinical criteria for high cardiovascular risk and statin intolerance; your GP will determine suitability.
The tablet should be swallowed whole; crushing or splitting may affect absorption and is not recommended.
Bempedoic acid is an oral cholesterol-lowering medication approved for use in adults with hypercholesterolaemia, particularly when statins are unsuitable, not tolerated, or when additional LDL-cholesterol reduction is needed. It is marketed in the United Kingdom under brand names such as Nexletol and the fixed-dose combination Nexlizet (bempedoic acid + ezetimibe). The drug is supplied as a 180 mg pill taken once daily. In the UK, it is a prescription-only medicine regulated by the Medicines and Healthcare products Regulatory Agency (MHRA).
Bempedoic acid belongs to the class of ATP-citrate lyase (ACL) inhibitors. ACL is an enzyme that sits early in the cholesterol synthesis pathway, converting citrate to acetyl-CoA, a building block for cholesterol and fatty acids. By blocking ACL, bempedoic acid reduces the hepatic production of cholesterol, which leads to an up-regulation of LDL receptors on liver cells and increased clearance of LDL-cholesterol from the bloodstream.
Key pharmacologic points:
In the United Kingdom, bempedoic acid is indicated for:
The medication is intended for adults ≥ 18 years of age. Clinical trials (e.g., CLEAR Wisdom, CLEAR Harmony) demonstrated statistically significant reductions in LDL-C and modest improvements in other lipid parameters, supporting regulatory approval.
Current peer-reviewed evidence does not support routine off-label use of bempedoic acid for indications such as triglyceride-rich lipoprotein disorders, primary prevention in low-risk populations, or pediatric hypercholesterolaemia. Any such use would be considered experimental and must be guided by a specialist in lipidology.
These events are typically mild to moderate and resolve with continued therapy or dose adjustment.
Note: Patients should disclose all medications, supplements, and herbal products to their prescriber before starting bempedoic acid.
This article provides educational information about bempedoic acid and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
